|
FierceBiotech Names
Constellation Pharmaceuticals as
One of the “Fierce 15"
Biotech Companies of 2008
Constellation Pharmaceuticals is “Fierce,” on Leading
Edge of Biotech
CAMBRIDGE, MA – June 24,
2008 – Constellation
Pharmaceuticals announced today that it has been named
to the annual FierceBiotech “Fierce 15” list,
designating it as one of the top biotech companies of
2008. The editors of FierceBiotech evaluated hundreds of
privately-held firms based on company vision, revenue
potential, quality of deals, strength of technology,
partnerships, and competitive market position.
Constellation was determined to be one of the
“fiercest,” proven by their creativity and innovations
in the industry.
An internationally recognized daily newsletter reaching
more than 65,000 biotech and pharma industry
professionals, FierceBiotech provides subscribers with a
quick authoritative briefing on the day’s top stories,
with a special focus on drug discovery and clinical
trials.
"Constellation is a new
player in a new field: epigenetics," said John Carroll,
Editor of FierceBiotech. "A new class of drugs that can
regulate the epigenome can play a major role in gene
expression, and that in turn can play a major role in
controlling disease. With three of the top scientists in
the field providing the brain trust, a solid lineup of
leading venture investors supplying the money and a
well-known biotech entrepreneur at the helm,
Constellation is off to a solid start."
Constellation
Pharmaceuticals is the first biopharmaceutical company
dedicated to the discovery and development of novel
drugs targeting selective regulators of epigenetic
function, In April, Constellation closed a $32 million
Series A financing. Presently, the company is
establishing its discovery platform and building a
preclinical pipeline of epigenetic drugs.
"FierceBiotech is
renowned for its advanced understanding of biotechnology
companies and the industry as a whole," said Mark Levin,
Chief Executive Officer of Constellation. "Being
selected as a member of the ‘Fierce 15’ is an honor that
highlights Constellation’s potential to make a
significant impact in the biotech market through
leveraging epigenetics, the next biological breakthrough
offering promise for targeting disease above and beyond
the genome.”
The Fierce 15 celebrates
the spirit of being “fierce” – championing innovation
and creativity, even in the face of intense competition.
The complete list of ‘Fierce 15’ companies is available
in today’s issue of FierceBiotech and on the
FierceBiotech Web site at
www.fiercebiotech.com.
About Constellation Pharmaceuticals
Constellation Pharmaceuticals is the first
biopharmaceutical company dedicated to the development
of novel therapeutics in the emerging field of
Epigenetics, a new field of science which is focused on
selective regulators of epigenetic function, which are
critical to controlling gene function and expression.
Constellation’s primary focus is in oncology, but the
company’s platform will also be applicable to other
therapeutics areas including autoimmune, inflammatory
and neurological diseases. The Company’s founders
represent the core thought leaders in Epigenetics,
responsible for key advances, insights and discoveries
in the field. Constellation Pharmaceuticals is located
in Cambridge, Massachusetts. For more information,
please visit the company’s website at
www.constellationpharma.com.
About
FierceMarkets
FierceMarkets is a digital business media
company serving vertical markets with email newsletters,
web sites, and live events. Based in Washington, DC,
FierceMarkets publications reach more than 450,000
executives in over 100 countries every business day.
Current publications include The Business VoIP Report (http://www.businessvoipreport.com),
FierceBioResearcher (http://www.fiercebioresearcher.com),
FierceBiotech (http://www.fiercebiotech.com),
FierceBroadbandWireless (http://www.fiercebroadbandwireless.com),
FierceCIO (http://www.fiercecio.com),
Fierce CIO: Tech Watch (http://www.fiercecio.com/techwatch),
FierceDeveloper (http://www.fiercedeveloper.com),
FierceFinance (http://www.fiercefinance.com),
FierceFinanceIT (http://www.fiercefinanceit.com),
FierceHealthCare (http:///www.fiercehealthcare.com),
FierceHealthFinance (http://www.fiercehealthfinance.com),
FierceHealthIT (http://www.fiercehealthit.com),
FierceIPTV (http://www.fierceiptv.com),
FierceMobileContent (http://www.fiercemobilecontent.com),
FierceMobileIT (http://www.fiercemovbileit.com),
FierceOnlineVideo (http://www.fierceonlinevideo.com),
FiercePharma (http:www.fiercepharma.com), FierceSarbox (http://www.fiercesarbox.com),
FierceTelecom (http://www.fiercetelecom.com),
FierceVaccines (http://www.fiercevaccines.com),
FierceVoIP (http://www.fiercevoip.com),
FierceWireless (http://www.fiercewireless.com),
and FierceWireless: Europe (http://www.fiercewireless.com/europe).
###
MEDIA CONTACTS
For Constellation:
Adriana Jenkins
Yates Public Relations
617-744-1713
adrianajenkins@gmail.com
Heather Cox
FierceMarkets, Inc.
202-628-8778 x13
heather@fiercemarkets.com
|
